Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial). This is an ASCO ...

Dr. Reddy’s Laboratories Ltd. on Wednesday announced the launch of Lenalidomide Capsules in the United States market. According to the company, this is the therapeutic equivalent generic version of ...

Mantle cell lymphoma (MCL) is an aggressive B-cell neoplasm characterized by the translocation t(11;14)(q13;q32) that leads to aberrant overexpression of cyclin D1 and a number of secondary ...

Data from a large phase III trial presented at the 2022 American Society of Hematology (ASH) annual meeting examined the relationship between minimal residual disease, progression-free survival, and ...

Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis. While there was no significant ...

Please provide your email address to receive an email when new articles are posted on . Lenalidomide resulted in a prolonged time to subsequent therapy in high-risk CLL. Lenalidomide did not seem to ...

The recommended starting dosage of lenalidomide for the treatment of MM is 25 mg/day p.o. on days 1-21 of a 28-day cycle. On the basis of the trials previously presented, the recommended dosage of ...

Lenalidomide (Revlimid, Celgene) is an immunomodulating agent. It belongs to a class of agents often referred to as immunomodulatory derivatives, which are all structural derivatives of thalidomide.

As a precursor to myeloma, smoldering multiple myeloma (MM) currently has no treatment. In fact, the standard of care is observation until the patient starts to present with symptoms. However, ...

The appraisal committee considered evidence submitted by Celgene, a review of this submission by the evidence review group (ERG), NICE's technical report, and responses from stakeholders. See the ...

Dr. Reddy’s licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after the March 2022 date previously granted to Natco Dr. Reddy’s also licensed ...